Following a predoctoral training in the field of aging, Dr Serra gained a Marie Curie postdoctoral fellowship to study chemoresitance at the Institute of Pathology, Humboldt University, Berlin. In 2004, she moved back to Spain to the National Cancer Research Center (CNIO, Madrid), where she further developed her interest cancer and inflammation. With a deep interest in developing her scientific career closer to the patient side, she was motivated by Dr José Baselga’s research at VHIO, which combined a profound molecular understanding of cancer biology with state-of-the-art targeted treatments. She established the PI3K-signaling research line in the laboratory, to study the mode of action and mechanisms of resistance to PI3K-pathway inhibitors. She has been part of numerous studies describing the compensatory effects following PI3K blockade in tumor cells and mechanisms of resistance to PI3K inhibitors (Serra et al, CR 2008; Serra et al, Oncogene 2011; Serra/Eichhorn, JCI 2013; Serra/Yan et al, CCR 2013). Her actual studies focus on understanding the subsets of activity of these reagents in vivo and potential combinations partners with clinical applicability (Ibrahim et al, CD 2013; Dienstmann et al, MCT 2014; García-García/Rivas et al, CCR 2015).